×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Kristie L. Kahl
Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.
Kristie L. Kahl
Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.
Katie Kosko and Jessica Skarzynski
The importance of teamwork between patients and their caregivers was a common theme at the second annual Ovarian Cancer Heroes event held in Honolulu, Hawaii.
Kristie L. Kahl
In this week’s episode, we spoke with actor Scott Foley, who opened up about his experience as a caregiver to his mother after her ovarian cancer diagnosis and why he joined the Not on My Watch movement to help educate others.
Alexandra Guadagno
From shark genomes to celebs and important updates, here is a quick overview of what is making headlines in the cancer space.
Beth Fand Incollingo
“Love, Gilda” fea­tures never-before-seen diaries, audio and videotapes from the collection of Gilda Radner, who died at age 42 of ovarian cancer.
Kristie L. Kahl
This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.
Kristie L. Kahl
Researchers are evaluating the use of folate receptors to treat platinum-resistant ovarian cancer.
Katie Kosko
Nearly 90 percent of women experienced sexual dysfunction; however, providers were not openly communicating about this side effect, according to survey results.
There is a flood of information available about genetic tests for cancer risk in the media, and even at community events, such as health fairs and senior centers. If these promotions have caught your attention and you are considering testing, there is important information that you should know first. 
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other